Correlation Between Corvus Pharmaceuticals and Decibel Therapeutics

Can any of the company-specific risk be diversified away by investing in both Corvus Pharmaceuticals and Decibel Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Corvus Pharmaceuticals and Decibel Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Corvus Pharmaceuticals and Decibel Therapeutics, you can compare the effects of market volatilities on Corvus Pharmaceuticals and Decibel Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Corvus Pharmaceuticals with a short position of Decibel Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Corvus Pharmaceuticals and Decibel Therapeutics.

Diversification Opportunities for Corvus Pharmaceuticals and Decibel Therapeutics

0.17

Correlation Coefficient

Corvus Pharmaceuticals  Decibel Therapeutics

Average diversification

The 3 months correlation between Corvus and Decibel is 0.17. Overlapping area represents the amount of risk that can be diversified away by holding Corvus Pharmaceuticals and Decibel Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Decibel Therapeutics and Corvus Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Corvus Pharmaceuticals are associated (or correlated) with Decibel Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Decibel Therapeutics has no effect on the direction of Corvus Pharmaceuticals i.e., Corvus Pharmaceuticals and Decibel Therapeutics go up and down completely randomly.

Pair Corralation between Corvus Pharmaceuticals and Decibel Therapeutics

Given the investment horizon of 90 days Corvus Pharmaceuticals is expected to generate 0.99 times more return on investment than Decibel Therapeutics. However, Corvus Pharmaceuticals is 1.01 times less risky than Decibel Therapeutics. It trades about 0.11 of its potential returns per unit of risk. Decibel Therapeutics is currently generating about 0.05 per unit of risk. If you would invest  80.00  in Corvus Pharmaceuticals on September 4, 2024 and sell it today you would earn a total of  745.00  from holding Corvus Pharmaceuticals or generate 931.25% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	30.71%
Values	Daily Returns

Corvus Pharmaceuticals  vs.  Decibel Therapeutics

Corvus Pharmaceuticals

Risk-Adjusted Performance

19 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Corvus Pharmaceuticals are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Corvus Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

Decibel Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Decibel Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Decibel Therapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Corvus Pharmaceuticals and Decibel Therapeutics

The main advantage of trading using opposite Corvus Pharmaceuticals and Decibel Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Corvus Pharmaceuticals position performs unexpectedly, Decibel Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Decibel Therapeutics will offset losses from the drop in Decibel Therapeutics' long position.

The idea behind Corvus Pharmaceuticals and Decibel Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.